← Back to patent-cliff list
CAS 1370651-34-5
Codes: ENSAR-007
Application context (from source-drug indications)
Non-small cell lung cancerEnsartinib HydrochlorideLung cancerEnsartinib HydrochlorideBrain metastasesEnsartinib HydrochlorideNon-Hodgkin lymphomaEnsartinib HydrochlorideHepatoblastomaEnsartinib HydrochlorideOsteosarcomaEnsartinib Hydrochloride
Source drugs (routes using this intermediate)
| Drug | Tier | Expiry |
|---|---|---|
| Ensartinib Hydrochloride | Tier C — Watch / trade | - |
Position in synthesis routes (up/downstream chain)
Ordered by route registration; left → right is the synthesis direction. The highlighted node is the current CAS; others link to their own profiles.
3,6-dichloropyridazine→6-chloropyridazin-3-amine→4-bromo-6-chloropyridazin-3-amine→1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol→(R)-6-chloro-4-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridazin-3-amine→ENSAR-006→ENSAR-007→ENSAR-008→methyl 4-aminobenzoate→ENSAR-010→ENSAR-011→(2R,6S)-2,6-dimethylpiperazine→ENSAR-013→1-(2,6-dichloro-3-fluorophenyl)ethan-1-ol
Intermediates available on this site
No listed intermediates for this target yet — send an RFQ directly and it will enter our matching pool.
This is a CAS-level registry record: registrations across routes are merged. Supplier offers and buyer demands will be matched on this CAS as the primary key.